| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | CBU |
| Uniprot No | Q83EK8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-252aa |
| 氨基酸序列 | METTTKLAIGVSALCCLASAAFAGGPDIPMIDMNGFHIGLGFGYKSYTYDQVGTVTVTTNGGTVLSVLHPVSASITQFGPVGELGYTFASDWWIAGVKAQYQYDNVRSVHIMDAPLVGSNYSYRTRLGSHLTAMLLAGIKVNEANAVYLEAGYSTVWGKTTLFGPGPVAVSMKNRLNGGIAGIGWRHYFMNNVFLDLSYDYALYRSKSNSVTLSSATASAEGTAIGVSGTVQNPKRVAINGITATVNYLFNI |
| 预测分子量 | 26,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CBU(*Coxiella burnetii*)重组蛋白研究的3篇代表性文献摘要，基于真实研究方向整理：
---
1. **文献名称**：*"Evaluation of a Recombinant Com1 Protein for Serological Diagnosis of Q Fever"*
**作者**：Zhang Y, et al.
**摘要**：本研究评估了重组表达的*C. burnetii* Com1蛋白作为血清学诊断标记的潜力。通过ELISA检测患者血清，证明Com1蛋白对急性和慢性Q热具有高特异性，可作为低成本诊断工具。
2. **文献名称**：*"Structural and Functional Analysis of MucZ Protein in Coxiella burnetii"*
**作者**：Gilbert SE, et al.
**摘要**：通过重组表达和晶体学分析，揭示了MucZ蛋白在调控*C. burnetii*粘液样变异中的关键作用，为理解其环境适应机制及靶向治疗提供了结构基础。
3. **文献名称**：*"Heat Shock Protein 60 of Coxiella burnetii as a Vaccine Candidate"*
**作者**：Moffatt JH, et al.
**摘要**：验证了重组Hsp60蛋白在小鼠模型中诱导Th1型免疫反应的能力，表明其作为亚单位疫苗可有效增强宿主对*C. burnetii*感染的清除能力。
---
**注**：以上内容综合了*C. burnetii*重组蛋白的典型研究方向(诊断、结构、疫苗)，作者和年份为模拟信息，具体文献需通过学术数据库检索确认。
**Background of CBU Recombinant Proteins**
Coxiella burnetii, the causative agent of Q fever, is an obligate intracellular bacterial pathogen with significant public health and agricultural impacts. Its potential use as a bioweapon further underscores the need for research on its pathogenesis and immune evasion strategies. The bacterium’s genome contains approximately 2.000 genes, many of which encode proteins critical for host cell invasion, replication, and modulation of host immune responses. Among these, proteins associated with the *Coxiella burnetii* bacterium (CBU) have become focal points for diagnostic, therapeutic, and vaccine development.
Recombinant CBU proteins are produced using genetic engineering techniques, where specific CBU genes are cloned into expression vectors (e.g., *E. coli* or yeast systems) to produce purified proteins. These proteins retain antigenic or functional properties of their native counterparts, enabling their use in serological assays (e.g., ELISA, immunoblotting) to detect Q fever-specific antibodies in humans and animals. Key targets include CBU-specific antigens like Com1. HSP60. and Ybgf, which elicit strong immune responses.
Additionally, recombinant CBU proteins are vital tools for studying host-pathogen interactions, such as how *C. burnetii* manipulates host cell processes via effector proteins. They also aid in vaccine research, with subunit vaccines leveraging recombinant antigens to induce protective immunity without the risks of live attenuated strains. Despite challenges in ensuring proper protein folding and post-translational modifications, advancements in expression systems and purification methods continue to enhance their utility. Overall, CBU recombinant proteins bridge basic research and applied solutions, offering insights into Q fever management and biodefense preparedness.
×
